- Home
- EVF vs RLMD Comparison
EVF vs RLMD Comparison
Compare EVF & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVF
- RLMD
- Stock Information
- Founded
- EVF 1998
- RLMD 2004
- Country
- EVF United States
- RLMD United States
- Employees
- EVF N/A
- RLMD N/A
- Industry
- EVF Investment Managers
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- EVF Finance
- RLMD Health Care
- Exchange
- EVF Nasdaq
- RLMD Nasdaq
- Market Cap
- EVF 101.0M
- RLMD 81.3M
- IPO Year
- EVF N/A
- RLMD N/A
- Fundamental
- Price
- EVF $5.42
- RLMD $3.31
- Analyst Decision
- EVF
- RLMD Hold
- Analyst Count
- EVF 0
- RLMD 2
- Target Price
- EVF N/A
- RLMD $1.00
- AVG Volume (30 Days)
- EVF 93.3K
- RLMD 1.5M
- Earning Date
- EVF 01-01-0001
- RLMD 11-13-2025
- Dividend Yield
- EVF 10.68%
- RLMD N/A
- EPS Growth
- EVF N/A
- RLMD N/A
- EPS
- EVF 0.94
- RLMD N/A
- Revenue
- EVF N/A
- RLMD N/A
- Revenue This Year
- EVF N/A
- RLMD N/A
- Revenue Next Year
- EVF N/A
- RLMD N/A
- P/E Ratio
- EVF $6.74
- RLMD N/A
- Revenue Growth
- EVF N/A
- RLMD N/A
- 52 Week Low
- EVF $5.20
- RLMD $0.24
- 52 Week High
- EVF $6.84
- RLMD $3.71
- Technical
- Relative Strength Index (RSI)
- EVF 43.31
- RLMD 72.37
- Support Level
- EVF $5.38
- RLMD $2.42
- Resistance Level
- EVF $5.50
- RLMD $2.86
- Average True Range (ATR)
- EVF 0.04
- RLMD 0.31
- MACD
- EVF 0.00
- RLMD 0.07
- Stochastic Oscillator
- EVF 33.36
- RLMD 76.93
About EVF Eaton Vance Senior Income Trust
Eaton Vance Senior Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to provide a high level of current income consistent with the preservation of capital, by investing in senior, secured floating-rate loans. The trust invests in below-investment-grade floating-rate loans, which are considered speculative because of the credit risk of their issuers. Its portfolio of investment consists of aerospace and defense, automotive, beverage, building and development, business equipment and services, cable and satellite television, and other areas.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.